Fluvoxamine – Maybe the Perfect Covid Drug?

In an earlier post, I pushed for more emphasis on Covid therapeutics (Covid Therapeutics Take a Back Seat). I mentioned fluvoxamine in a list of promising drugs that should be considered. Today, I want to talk more about this old drug that might be just the right answer for this new pandemic.

Two new oral treatments of Covid were just approved by the FDA last week, Paxlovid and Molnupiravir. Paxlovidhas reduced hospitalizations by about 90% and Molnupiravir has reduced hospitalizations by about 50%. While these drugs are exciting new therapeutic options for Covid treatment, they are currently available in very limited quantities. Pfizer expects to manufacture 180,000 courses by the end of 2021, but that’s far from the needed supply. Molnupiravir may be in even scarcer supply. This means rationing of treatment with these drugs. There are also some concerns Molnupiravir may cause DNA mutations in rare cases.

Fluvoxamine, however, is a pill that has been in widespread usage since 1994 for treatment of obsessive-compulsive disorders. Doctors often prescribe it for other disorders, such as anxiety, depression, and panic attacks, a practice known as “off label” usage. This is quite common in the medical profession as a drug or device is approved for one use, but doctors then find it is also useful for another condition.

Allysia Finley, writing in The Wall Street Journal, tells us studies show that fluvoxamine is highly effective at preventing hospitalization in Covid patients, and it’s unlikely to be blunted by the new Omicron variant. Doctors hypothesize that fluvoxamine can trigger a cascade of reactions in cells that modulate inflammation and interfere with virus functions. It could thus prevent an overreactive immune response to pathogens – a process known as a cytokine storm. Cytokine storms can lead to organ failure and death. Fluvoxamine can also increase nighttime levels of melatonin – the hormone that makes you sleepy – which evidence suggests can also mitigate inflammation.

What is the clinical evidence that fluvoxamine works? A large study in France during the early months of the pandemic found that Covid-19 patients treated with selective reuptake inhibitors, such as fluvoxamine, were significantly less likely to be intubated or die. A small randomized control trial last year by psychiatrists at the Washington University School of Medicine in St. Louis was a spectacular success: None of the 80 participants who started fluvoxamine within seven days of developing symptoms deteriorated. However, 6 of the 72 patients in the control group got worse, and four were hospitalized. These results were published in November, 2020 in the Journal of the American Medical Association (JAMA), inspiring a real-world experiment.

Soon after the study was published, there was a Covid outbreak among employees at the Golden Gate Fields horse racing track in Berkeley, California. The physician at the track offered fluvoxamine to the workers. After 14 days, none of the 65 patients who took it were hospitalized or still had symptoms. But of the 48 who didn’t take the drug, 6 (12.5%) were hospitalized and one died. Twenty-nine had lingering symptoms, which might have resulted from inflammatory damage to their organs.

Other studies have had similar dramatic results. Researchers at McMaster University in Hamilton, Ontario, last winter launched a large clinical trial in Brazil. The results from their trial were published in the Lancet medical journal in October. Fluvoxamine reduced the odds of hospitalization or emergency care by 66% and death by 90% among unvaccinated high-risk patients who mostly followed the treatment regimen – compared to monoclonal antibodies. There was no difference in adverse effects between the fluvoxamine and placebo groups.

Here is the best part – a 10-day course of fluvoxamine costs $4, compared with the $2100 the U.S. government has been paying for monoclonal antibodies, and $530 to $700 for a course of the Pfizer and Merck oral treatments. Multiple drug makers manufacture fluvoxamine and could ramp up supply without much difficulty were demand to increase.

There is no need for the FDA to grant Emergency Use Authorization (EUA) for doctors to prescribe this drug now. However, many doctors may be reluctant to prescribe it without EUA or NIH recommendations. Physicians have been investigated by state medical boards for prescribing other “off label” drugs for Covid, such as ivermectin.

The perfect Covid treatment would have the following characteristics:

  • Effective in reducing hospitalizations and death
  • Oral treatment available at home
  • Proven safety record over many years
  • Readily available
  • Low cost

Fluvoxamine checks all of these boxes. What’s not to like? It’s time the FDA, CDC, and NIH all realize this may be the drug we have all been waiting for.

Best Books of 2021

 

Regular readers of this blog know every year at this time I devote my first post of the year to my top ten books I read in the last year. It’s the time of the year when people make New Year’s resolutions, and I suggest you make a resolution to read at least two books a month.

I made that resolution in 1998 and have kept it every year since. Since that time, I’ve read 992 books! I can’t tell you how much that has influenced my life in a positive way. It’s rare to remember a television program you watched last night, but a book stays with you forever. You will be more informed, even if you read a lot of fiction.

Here are my top ten books for 2021 in no particular order:

  1. Blackout – Candace Owens – If you watch Fox News, you’ve probably seen this extremely articulate and impressive young black woman who refuses to accept the politically correct narrative concerning blacks in America. This book is must-reading if you’re to understand how government policies are hurting blacks.
  2. Rocket Men – The Daring Odyssey of Apollo 8 and the Astronauts Who Made Man’s First Journey to the Moon – Robert Kurson – A fascinating look at the Apollo 8 mission from an insider’s perspective; a real-life story of human achievement.
  3. A Time for Mercy – John Grisham – Although fiction, this is a great read from one of America’s great storytellers who gave us the opposite perspective in his first book, A Time to Kill.
  1. The Last Trial – Scott Turow – Another great fiction read from one of the best legal fiction writers. It gives one perspective on life from an elder lawyer’s point of view.
  1. Unsettled – What Climate Science Tells Us, What It Doesn’t, and Why It Matters – Steven E. Koonin – If you think you know all about climate change, this book will change your opinion. Dr. Koonin is a physicist and former Undersecretary for Science, U.S. Department of Energy under the Obama Administration. He makes it clear that climate change is real, but should not be alarming.
  2. Killing the Mob – Bill O’Reilly/Martin Dugard – This is an insightful look back at the era of mob violence in the early part of the last century and the fight to defeat organized crime in America. This team of authors makes history exciting!
  3. The Law of Innocence – Michael Connelly – A great fiction read from the creator of Harry Bosch and the Lincoln Lawyer.
  4. Countdown Bin Laden – Chris Wallace – A well-written account of the killing of Osama Bin Laden with new insights into the decision-making behind the scenes and the complexity of the actual operation. Wallace adds a lot to this well-known story.
  5. The Dying Citizen – Victor Davis Hanson – An insightful look at what is happening in our country to change the meaning of the word “citizen.” Hanson, a Stanford professor of military history and the classics, is one of America’s great scholars, writers, and political observers.
  6. Woke, Inc. – Inside Corporate America’s Social Justice Scam – Vivek Ramaswamy – This first-generation American entrepreneur founded Roivant in 2014 and led the largest biotech IPOs of 2015 and 2016. His brilliant mind understands what is happening in the “woke” corporate world that threatens our democracy.

 

There you have it, my best ten books of the last year. They are a mix of heavy, intellectual reading and just reading for fun and excitement. Hope you enjoy them – and keep reading!

Vaccine Boosters for Teens or Not?

The new Omicron variant has President Biden and the CDC calling for vaccine boosters for everyone, even teens. What is the scientific basis for this?

Dr. Marty Makary, Johns Hopkins Medical School, questions the wisdom of this advice in an article just published in The Wall Street Journal. According to a large Israeli population study, published in The New England Journal of Medicine, the risk of Covid death in people under 30 with two vaccine shots was zero.

Since this study clearly was undertaken before the Omicron variant was widely spread, this reflects the impact of the more dangerous Delta or Alpha variants. The Omicron variant is clearly less dangerous as only one death has been reported to date in the U.K. and one recently in Texas. Yet the Omicron variant is now believed to be present in about 74% of new Covid infection cases. All this makes the danger of Covid-19 death in teenagers quite low, perhaps zero, especially if they have been vaccinated twice.

Why not just give them boosters anyway? Makary tells us there are infrequent, but real risks. In a study of 438,511 males 16 to 24, 56 developed myocarditis after their second Pfizer dose. That’s one in every 7,830 cases, or seven times the usual rate. While most cases were mild, in the broader group of 136 people including older and female patients, who developed myocarditis after the vaccine, seven had a “complicated course” and one 22-year-old died. The incidence of this complication is even higher with the Moderna vaccine, which is why some European countries have restricted it for people under 30.

But in the U.S., the FDA and the CDC are indiscriminately pushing for boosters for all young people. Some colleges are imposing booster mandates for all their students, despite the good health in most college students. Who made these recommendations?

Makary tells us the last vote by FDA scientific advisers, held in September, rejected the proposal 16 – 2. FDA leaders revisited the proposal in November and simply bypassed the experts they usually rely upon. The same is true of the CDC; their advisors also rejected boosters for people who were not at high risk. Two FDA top scientists, including the head of the agency’s vaccine efforts, resigned around the time of the September vote over White House pressure to authorize boosters for all. They wrote in detail about their concerns. (All this took place before the less dangerous Omicron variant was even the dominant virus.)

Now a study by Oxford researchers, published last week in Nature Medicine, has validated the concerns of these advisors. It found young people suffered myocarditis, pericarditis and arrhythmias more frequently from vaccines than from Covid itself. And the long-term cardiac effects of boosters in young people are unknown.

All of this seems to be coming in response to the Omicron variant. Although this variant is clearly more infectious, with doubling times now estimated at two to three days, the preliminary data thus far has shown it to be a mild, less dangerous variant. A University of Hong Kong study found that Omicron is less than one-tenth as infective in lung cells compared with the Delta variant. That explains why Omicron patients report far fewer cough and fever symptoms. Instead, they report common cold-symptoms, similar to the four known seasonal coronaviruses that have circulated for decades and account for the “common cold.”

Case counts are already plunging in South Africa, the epicenter of this new variant, and not one death has been reported there. South African Health Minister Joe Phaahla reports that only 1.7% of these Covid patients were hospitalized when this became the dominant variant as compared to 19% with the Delta variant.

With such a mild disease becoming the dominant variant, it would seem booster mandates, especially for young people, make little sense. They certainly would not be “following the science.”